A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release (PR) in Patients With Early Stage Parkinson's Disease.
Phase of Trial: Phase IV
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms TANDEM-662
- Sponsors GlaxoSmithKline
- 11 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Feb 2012 Actual initiation date (1 Jan 2012) added as reported by ClinicalTrials.gov.